Rogco LP Boosts Stock Holdings in Eli Lilly and Company $LLY

Rogco LP grew its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3,975.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 489 shares of the company’s stock after buying an additional 477 shares during the quarter. Rogco LP’s holdings in Eli Lilly and Company were worth $373,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Laurel Wealth Advisors LLC lifted its position in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank purchased a new stake in Eli Lilly and Company during the 2nd quarter valued at $8,827,714,000. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after acquiring an additional 1,183,038 shares during the last quarter. Franklin Resources Inc. grew its holdings in Eli Lilly and Company by 13.4% in the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after acquiring an additional 564,736 shares during the last quarter. Finally, Canada Pension Plan Investment Board increased its position in shares of Eli Lilly and Company by 87.2% in the second quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock valued at $898,238,000 after acquiring an additional 536,679 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 3.6%

LLY opened at $1,078.98 on Thursday. The stock has a market cap of $1.02 trillion, a PE ratio of 52.79, a PEG ratio of 0.78 and a beta of 0.35. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The business has a 50 day moving average of $1,055.07 and a 200-day moving average of $876.57. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s payout ratio is presently 29.35%.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA grants Breakthrough Therapy designation to Lilly’s ovarian-cancer candidate sofetabart (mipitecan), accelerating regulator engagement and potentially speeding development for a high‑need oncology indication. FDA Grants Breakthrough Therapy Tag to LLY’s Ovarian Cancer Candidate
• Positive Sentiment: Lilly announces SURMOUNT-REAL UK, a phase 4 real-world study of tirzepatide (obesity), which, if supportive, could broaden real‑world uptake and long‑term market potential for its GLP‑1 franchise. Lilly’s SURMOUNT-REAL UK Trial: Real-World Test of Tirzepatide’s Obesity Upside
• Positive Sentiment: Retatrutide trial update links weight-loss therapy to potential knee osteoarthritis relief — a signal that obesity drugs may unlock additional labeled uses and payor value. Eli Lilly’s Retatrutide Trial Links Obesity Treatment With Knee Osteoarthritis Relief Potential
• Positive Sentiment: Lilly opens a phase 2 trial for a new oral pain candidate targeting diabetic nerve pain, expanding its non‑GLP-1 pipeline and future revenue diversification. Eli Lilly Expands Its Pain Pipeline With New Phase 2 Trial in Diabetic Nerve Pain
• Positive Sentiment: Market commentary and analyst previews (Seeking Alpha, MarketBeat, Zacks) are bullish ahead of earnings, highlighting Mounjaro/Zepbound sales and pipeline catalysts as drivers for higher valuations. Eli Lilly: Buy Ahead Of Its Earnings Day (Preview)
• Neutral Sentiment: Lilly confirmed its Q4 2025 results and conference call for Feb. 4, 2026 — a near-term liquidity/event date that will likely set the next major directional cue. Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
• Neutral Sentiment: Guggenheim slightly trimmed its price target (from $1,163 to $1,161) but kept a buy rating — a marginal analyst tweak that is unlikely to materially change the investment thesis. LLY price target lowered by Guggenheim
• Neutral Sentiment: Rumors about a potential Abivax takeover involving Lilly were downplayed by Abivax’s CEO, reducing speculative takeover chatter. Abivax CEO Dismisses Rumors of Eli Lilly Takeover
• Negative Sentiment: A Seeking Alpha piece on Novo Nordisk’s new CEO frames a potential intensifying rivalry; stronger competition from Novo could pressure Lilly’s longer-term market share in GLP‑1 products. Novo Nordisk: How Inspiring New CEO Will Take Fight To Key Rival Eli Lilly In 2026

Analyst Ratings Changes

LLY has been the topic of several recent analyst reports. Scotiabank assumed coverage on Eli Lilly and Company in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 target price on the stock. The Goldman Sachs Group lifted their price objective on Eli Lilly and Company from $951.00 to $1,145.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Berenberg Bank upped their target price on Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. Finally, UBS Group initiated coverage on shares of Eli Lilly and Company in a report on Tuesday, January 6th. They issued a “buy” rating and a $1,250.00 price target on the stock. Four equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Buy” and an average target price of $1,174.61.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.